Alvotech has 2 Schedule 13D or 13G filings on record since 2026-03-12. 2 holders' latest filing reports 5% or more of ordinary shares. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Aztiq Pharma Partners S.a r.l. | 33.3% | 103,849,420 | SCHEDULE 13D/A, 2026-03-12 | 2025-12-17 |
| Celtic Holdings S.C.A. | 27.5% | 107,450,988 | SCHEDULE 13D/A, 2026-06-30 | 2026-06-26 |
Purpose of Transaction (Item 4)
Celtic Holdings S.C.A.
Item 4 is hereby amended and supplemented as follows: On June 26, 2026, Celtic Lux purchased aggregate of 10,133,333 Ordinary Shares, at a price of $3.75 per share, for an aggregate investment of $38,000,000 (such investment, the "PIPE Investment") pursuant to the terms of a subscription agreement (the "Subscription Agreement") dated June 16, 2026, by and between Celtic Lux and the Issuer. In connection with the PIPE Investment, pursuant to the Subscription Agreement, Celtic Lux was granted registration rights pursuant to which Celtic Lux may, at any time and from time to time, make a written demand for registration under the Securities Act of 1933, as amended, of all or any portion of the shares purchased by it in the PIPE Investment on any available form of registration statement (a "Demand Registration"), including by way of an underwritten offering with underwriters selected by Celtic Lux and reasonably acceptable to the Issuer. The Issuer is obligated, using its reasonable best efforts and as expeditiously as possible after receipt of such demand, to prepare and file with the SEC a registration statement covering the resale of such shares and to keep such registration statement effective until all such shares have been disposed of or withdrawn. The Issuer is not obligated to effect more than two (2) Demand Registrations in total. The Issuer has the right to defer any Demand Registration for up to 60 days in total, or 30 consecutive days, in any 12-month period if the …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-06-30; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-03-12 | Aztiq Pharma Partners S.a r.l. | 33.3% | SCHEDULE 13D/A |
| 2026-06-30 | Celtic Holdings S.C.A. | 27.5% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for Alvotech. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.